Niroja Vadagam
Niroja Vadagam has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Sharath Babu Haridasyam
Department of Chemistry GITAM School of Science (Deemed to be University) Hyderabad India
9 shared publications - Narasimha Swamy Lakka
Department of Chemistry, School of Applied Sciences and Humanities, VIGNAN’S Foundation for Science, Technology & Research, Vadlamudi, India
7 shared publications - Muvvala Venkatanarayana
Department of Chemistry, GITAM School of Science GITAM (Deemed to be) University Hyderabad India
6 shared publications - Sanjeeva R. Chinnakadoori
Department of Analytical Research and Development Amneal Pharmaceuticals Piscataway New Jersey USA
6 shared publications - N. V. V. D. Praveen Boppy
Department of Chemistry GITAM School of Science (Deemed to be University) Hyderabad Telangana India
4 shared publications - Mohan Pasham
Department of Chemistry GITAM School of Science (Deemed to be University) Hyderabad Telangana India
3 shared publications
Latest Publications
- 31 December 2025
- Published by Taylor & Francis in Journal of Liquid Chromatography & Related Technologies
- Vol. 49 (1-4) , 35-49
Role of evaporative light scattering detectors in HPLC and UPLC—a comprehensive review of operating principle and method development principles
- 31 December 2025
- Published by Taylor & Francis in Journal of Liquid Chromatography & Related Technologies
- Vol. 49 (1-4) , 35-49
Role of evaporative light scattering detectors in HPLC and UPLC—a comprehensive review of operating principle and method development principles
- 20 September 2025
- Published by Wiley in Separation Science Plus
- Vol. 8 (9)
Development and Validation of an Eco‐Friendly HPLC Method for the Quantification of Organic Impurities in Flecainide Acetate Bulk and Tablets: A Green Chemistry Assessment
Flecainide acetate (FA) is an antiarrhythmic medication that works by inhibiting cardiac sodium channels, offering local anesthetic effects. A liquid chromatography (LC) technique was newly established for separating and quantitating eight known organic impurities, including process‐related impurities, pharmacopeial impurities, and degradation products (DPs), along with all unknown impurities. Chromatographic separation was achieved on a C 18 analytical column using gradient mode, consisting of pH 5.1 ammonium formate buffer, acetonitrile, and methanol as binary mobile phases. Degradation testing was undertaken in a variety of stress conditions to assess stability‐indicating attributes. These conditions included exposure to 5 N HCl (70°C/4 h), 5 N NaOH (70°C/2 h), water (70°C/2 h), H 2 O 2 (30%, 70°C/2 h), dry heat (105°C/45 min), and photo‐light/7 days. This newly established high‐performance liquid chromatography (HPLC) technique underwent validation in accordance with the United States Pharmacopeia (USP) and International Council for Harmonisation (ICH) principles, encompassing aspects such as specificity, linearity, detection limit (DL), quantitation limit (QL), precision, solution stability, accuracy, and robustness. The QLs, linearity, and recovery results for FA and its eight known impurities ranged from 0.03% to 0.75% ( R 2 > 0.995) and 85.0%–115.0%, respectively. This approach is well‐suited for analyzing pharmaceutical formulations and bulk pharmaceuticals for impurity profiles and assay results of FA. The greenness of the proposed HPLC method was evaluated using the green chemistry tools of Analytical GREEnness (AGREE), National Environmental Methods Index (NEMI), and Analytical Method Greenness Score (AMGS).
- 20 September 2025
- Published by Wiley in Separation Science Plus
- Vol. 8 (9)
Development and Validation of an Eco‐Friendly HPLC Method for the Quantification of Organic Impurities in Flecainide Acetate Bulk and Tablets: A Green Chemistry Assessment
Flecainide acetate (FA) is an antiarrhythmic medication that works by inhibiting cardiac sodium channels, offering local anesthetic effects. A liquid chromatography (LC) technique was newly established for separating and quantitating eight known organic impurities, including process‐related impurities, pharmacopeial impurities, and degradation products (DPs), along with all unknown impurities. Chromatographic separation was achieved on a C 18 analytical column using gradient mode, consisting of pH 5.1 ammonium formate buffer, acetonitrile, and methanol as binary mobile phases. Degradation testing was undertaken in a variety of stress conditions to assess stability‐indicating attributes. These conditions included exposure to 5 N HCl (70°C/4 h), 5 N NaOH (70°C/2 h), water (70°C/2 h), H 2 O 2 (30%, 70°C/2 h), dry heat (105°C/45 min), and photo‐light/7 days. This newly established high‐performance liquid chromatography (HPLC) technique underwent validation in accordance with the United States Pharmacopeia (USP) and International Council for Harmonisation (ICH) principles, encompassing aspects such as specificity, linearity, detection limit (DL), quantitation limit (QL), precision, solution stability, accuracy, and robustness. The QLs, linearity, and recovery results for FA and its eight known impurities ranged from 0.03% to 0.75% ( R 2 > 0.995) and 85.0%–115.0%, respectively. This approach is well‐suited for analyzing pharmaceutical formulations and bulk pharmaceuticals for impurity profiles and assay results of FA. The greenness of the proposed HPLC method was evaluated using the green chemistry tools of Analytical GREEnness (AGREE), National Environmental Methods Index (NEMI), and Analytical Method Greenness Score (AMGS).
Principles for Stereoselective Separation of Chiral Drug Compounds Enantiomers and Diastereomers in Pharmaceuticals and Biopharmaceuticals Using Liquid Chromatography
In the fields of pharmaceuticals and biopharmaceuticals, chiral liquid chromatography techniques including high‐performance liquid chromatography and ultra‐performance liquid chromatography are frequently used to isolate, identify, separate, and quantify chiral isomers, including enantiomers and diastereomers (stereoisomers), due to the significant differences in biological activity and therapeutic effects of stereoisomers. The authors have provided a comprehensive overview of the fundamental principles necessary for using liquid chromatography to separate and accurately estimate chiral compounds that exhibit stereoisomerism (both enantiomers and diastereomers). The development strategies outlined include the selection of chromatographic conditions, optimization of sample preparation, evaluation of degradation pathways, establishment of system suitability criteria, and execution of method validation studies. Additionally, this article supports the development of robust and stability‐indicating methods by applying one factor at a time and design of experiments concepts for chiral drugs and their chiral impurities in pharmaceuticals and biopharmaceuticals. The method validation attributes essential to evaluate the characteristics of the developed method were discussed in this write‐up. The validation parameters include specificity, linearity, detection limit, quantitation limit, accuracy, precision, solution stability.
Principles for Stereoselective Separation of Chiral Drug Compounds Enantiomers and Diastereomers in Pharmaceuticals and Biopharmaceuticals Using Liquid Chromatography
In the fields of pharmaceuticals and biopharmaceuticals, chiral liquid chromatography techniques including high‐performance liquid chromatography and ultra‐performance liquid chromatography are frequently used to isolate, identify, separate, and quantify chiral isomers, including enantiomers and diastereomers (stereoisomers), due to the significant differences in biological activity and therapeutic effects of stereoisomers. The authors have provided a comprehensive overview of the fundamental principles necessary for using liquid chromatography to separate and accurately estimate chiral compounds that exhibit stereoisomerism (both enantiomers and diastereomers). The development strategies outlined include the selection of chromatographic conditions, optimization of sample preparation, evaluation of degradation pathways, establishment of system suitability criteria, and execution of method validation studies. Additionally, this article supports the development of robust and stability‐indicating methods by applying one factor at a time and design of experiments concepts for chiral drugs and their chiral impurities in pharmaceuticals and biopharmaceuticals. The method validation attributes essential to evaluate the characteristics of the developed method were discussed in this write‐up. The validation parameters include specificity, linearity, detection limit, quantitation limit, accuracy, precision, solution stability.
- 13 February 2024
- Published by Wiley in Separation Science Plus
- Vol. 7 (4)
Separation and quantification of organic‐related impurities of anti‐histamine drug hydroxyzine in pharmaceutical dosage forms using stability‐indicating high‐performance liquid chromatography, liquid chromatography‐mass spectrometry, and high‐resolution mass spectrometry techniques
A simple and robust high‐performance liquid chromatography (HPLC) method was developed for organic impurities of hydroxyzine hydrochloride in pharmaceuticals. The developed method was designed to estimate all organic impurities of hydroxyzine. The HPLC separation was achieved using C 18 column (150 × 3.9 mm, 5 μm) along with a binary gradient consisting of mobile phases A (0.1%, trifluoroacetic acid in purified water) and B (0.05%, trifluoroacetic acid in acetonitrile), a flow rate of 0.7–mL/min, a column temperature of 30°C and a sample temperature of 25°C. The detection wavelength used was 230 nm for the estimation of impurity‐A, impurity‐B, and all unspecified impurities and degradation products, whereas impurity‐C was quantitated using 254 nm. The stability‐indicating property of the developed HPLC technique was assessed using stress testing conditions of hydrolysis, oxidation, thermal, photo‐light, and humidity. The validation study was performed for the limit of detection and limit of quantification, linearity, and recoveries were 0.03%, 0.05%, and 0.1132–2.9920 μg/mL (R 2 > 0.999), and 84.09%–109.74%, respectively. The proposed method is highly suitable for the determination of assay, organic impurities, and degradation products of the hydroxyzine. The chemical structure of degradation product 1 (hydroxyzine N‐Oxide) and degradation product 2 (O‐Acetyl hydroxyzine) were identified with the supporting data of LC‐mass spectrometry (LC‐MS) and high‐resolution MS.
- 13 February 2024
- Published by Wiley in Separation Science Plus
- Vol. 7 (4)
Separation and quantification of organic‐related impurities of anti‐histamine drug hydroxyzine in pharmaceutical dosage forms using stability‐indicating high‐performance liquid chromatography, liquid chromatography‐mass spectrometry, and high‐resolution mass spectrometry techniques
A simple and robust high‐performance liquid chromatography (HPLC) method was developed for organic impurities of hydroxyzine hydrochloride in pharmaceuticals. The developed method was designed to estimate all organic impurities of hydroxyzine. The HPLC separation was achieved using C 18 column (150 × 3.9 mm, 5 μm) along with a binary gradient consisting of mobile phases A (0.1%, trifluoroacetic acid in purified water) and B (0.05%, trifluoroacetic acid in acetonitrile), a flow rate of 0.7–mL/min, a column temperature of 30°C and a sample temperature of 25°C. The detection wavelength used was 230 nm for the estimation of impurity‐A, impurity‐B, and all unspecified impurities and degradation products, whereas impurity‐C was quantitated using 254 nm. The stability‐indicating property of the developed HPLC technique was assessed using stress testing conditions of hydrolysis, oxidation, thermal, photo‐light, and humidity. The validation study was performed for the limit of detection and limit of quantification, linearity, and recoveries were 0.03%, 0.05%, and 0.1132–2.9920 μg/mL (R 2 > 0.999), and 84.09%–109.74%, respectively. The proposed method is highly suitable for the determination of assay, organic impurities, and degradation products of the hydroxyzine. The chemical structure of degradation product 1 (hydroxyzine N‐Oxide) and degradation product 2 (O‐Acetyl hydroxyzine) were identified with the supporting data of LC‐mass spectrometry (LC‐MS) and high‐resolution MS.
Separation and simultaneous estimation of enantiomers and Diastereomers of muscarinic receptor antagonist Solifenacin using stability‐indicating Normal‐phase HPLC technique with chiral stationary phase amylose tris‐(3,5‐dimethylphenylcarbamate)
The R,S‐enantiomer impurity and diastereomer impurities (S,S‐isomer and R,R‐isomer) of the solifenacin (S,R‐enantiomer) were effectively separated and quantified simultaneously utilizing normal‐phase high‐performance liquid chromatography with a chiral stationary phase consisting of amylose tris (3,5‐dimethylphenylcarbamate) coated on silica‐gel (Chiralpak, AD‐H). The enantiomeric and stereo‐selective separation was achieved within a run time of 35 minutes using a mobile phase of ‘n‐hexane, ethanol, and diethylamine’ in an isocratic elution mode with a detection wavelength of 220 nm. The validation attributes assessed were accuracy (which showed excellent recoveries between 97.5% and 100.4%) and linearity (which was proven in the range of 0.081–1.275 μg.mL−1, with a linear regression of 0.999). The stress testing experiments proved that the developed methodology by the HPLC technique has stability‐indicating characteristics, as all closely eluting peak pairs were separated well with a resolution of 2.3 and without any interference. The proposed methodology was highly efficient in separating and simultaneously determining the chiral impurities (enantiomers and diastereomers) of the solifenacin in the release and stability sample analyses of drug substances and tablets in pharmaceutical formulations.
Separation and simultaneous estimation of enantiomers and Diastereomers of muscarinic receptor antagonist Solifenacin using stability‐indicating Normal‐phase HPLC technique with chiral stationary phase amylose tris‐(3,5‐dimethylphenylcarbamate)
The R,S‐enantiomer impurity and diastereomer impurities (S,S‐isomer and R,R‐isomer) of the solifenacin (S,R‐enantiomer) were effectively separated and quantified simultaneously utilizing normal‐phase high‐performance liquid chromatography with a chiral stationary phase consisting of amylose tris (3,5‐dimethylphenylcarbamate) coated on silica‐gel (Chiralpak, AD‐H). The enantiomeric and stereo‐selective separation was achieved within a run time of 35 minutes using a mobile phase of ‘n‐hexane, ethanol, and diethylamine’ in an isocratic elution mode with a detection wavelength of 220 nm. The validation attributes assessed were accuracy (which showed excellent recoveries between 97.5% and 100.4%) and linearity (which was proven in the range of 0.081–1.275 μg.mL−1, with a linear regression of 0.999). The stress testing experiments proved that the developed methodology by the HPLC technique has stability‐indicating characteristics, as all closely eluting peak pairs were separated well with a resolution of 2.3 and without any interference. The proposed methodology was highly efficient in separating and simultaneously determining the chiral impurities (enantiomers and diastereomers) of the solifenacin in the release and stability sample analyses of drug substances and tablets in pharmaceutical formulations.
- 13 November 2023
- Published by Wiley in Separation Science Plus
- Vol. 7 (1)
Separation and quantification of organic‐related impurities of beta‐adrenergic receptor blocking agent propranolol in pharmaceutical solid dosage forms: Impurity profiling using stability‐indicating HPLC method
Propranolol hydrochloride (PPH) is a medication of beta‐adrenergic receptors. It is used to treat pediatric hemangiomas that are growing and need systemic therapy. A reversed‐phase high‐performance liquid chromatography (HPLC) was made to separate and estimate the amounts of ten known organic impurities of propranolol in bulk drugs, tablets, and capsule dosage forms. The chromatographic separation was achieved on a C 18 column (100 × 4.6 mm, 2.7 μm) using a binary gradient mixture of pH 2.3 phosphate buffer and organic modifiers of acetonitrile, methanol, and isopropyl alcohol as the mobile phase. The stability‐indicating character of the proposed method was proven using stress testing study. The test method was validated for specificity, limit of detection, limit of quantitation, linearity, precision, accuracy, and robustness. For the propranolol and its ten organic impurities, the limit of quantitation, linearity, and recoveries were found in a range of 0.0123–0.4266 μg/mL ( R 2 > 0.9982) and 89.2–98.9%, respectively. The proposed liquid chromatography method is found to be highly suitable for impurity profiling of propranolol in bulk drugs and pharmaceutical formulations (tablets and capsules).
- 13 November 2023
- Published by Wiley in Separation Science Plus
- Vol. 7 (1)
Separation and quantification of organic‐related impurities of beta‐adrenergic receptor blocking agent propranolol in pharmaceutical solid dosage forms: Impurity profiling using stability‐indicating HPLC method
Propranolol hydrochloride (PPH) is a medication of beta‐adrenergic receptors. It is used to treat pediatric hemangiomas that are growing and need systemic therapy. A reversed‐phase high‐performance liquid chromatography (HPLC) was made to separate and estimate the amounts of ten known organic impurities of propranolol in bulk drugs, tablets, and capsule dosage forms. The chromatographic separation was achieved on a C 18 column (100 × 4.6 mm, 2.7 μm) using a binary gradient mixture of pH 2.3 phosphate buffer and organic modifiers of acetonitrile, methanol, and isopropyl alcohol as the mobile phase. The stability‐indicating character of the proposed method was proven using stress testing study. The test method was validated for specificity, limit of detection, limit of quantitation, linearity, precision, accuracy, and robustness. For the propranolol and its ten organic impurities, the limit of quantitation, linearity, and recoveries were found in a range of 0.0123–0.4266 μg/mL ( R 2 > 0.9982) and 89.2–98.9%, respectively. The proposed liquid chromatography method is found to be highly suitable for impurity profiling of propranolol in bulk drugs and pharmaceutical formulations (tablets and capsules).
- 21 September 2023
- Published by Wiley in Separation Science Plus
- Vol. 6 (12)
Separation and quantitation of valacyclovir enantiomers using stability‐indicating chiral liquid chromatography method with a chiral stationary phase of amylose tris‐(3,5‐dimethylphenylcarbamate)
The present research developed and validated a new stability‐indicating technique for the stereo‐selectively enantiomers of the antiviral nucleoside analog Valacyclovir hydrochloride (VAL). The chiral separation was performed using normal‐phase high‐performance liquid chromatography (HPLC) with a chiral stationary phase consisting of amylose tris(3‐chloro‐5‐methylphenylcarbamate) and a mobile phase of “ n ‐hexane, methanol, ethanol, and diethylamine”, flow rate of 0.60 mL/min, column temperature of 30°C, injection volume of 10‐μL, detection wavelength of 254‐nm, and run time of 25‐min. The enantiomers (S‐enantiomer, L‐isomer, R‐enantiomer, and D‐isomer) of Valacyclovir were separated with a resolution of 4.8 and no interference. The validation parameters verified for the proposed method, linearity in a range of 0.1002–24.3486 μg/mL (0.02–4.86%) with a regression coefficient of 0.999, and the accuracy was determined with excellent recoveries ranging from 94.38%–109.97%. The concentrations established for the detection limit and quantitation limit were 0.01% and 0.02%, respectively. The forced degradation experiments were used to assess the stability‐indicating qualities. D‐Valacyclovir impurity was successfully evaluated in release and stability samples of VAL in drug substance and tablet dosage forms using the proposed normal phase chiral HPLC approach.
- 21 September 2023
- Published by Wiley in Separation Science Plus
- Vol. 6 (12)
Separation and quantitation of valacyclovir enantiomers using stability‐indicating chiral liquid chromatography method with a chiral stationary phase of amylose tris‐(3,5‐dimethylphenylcarbamate)
The present research developed and validated a new stability‐indicating technique for the stereo‐selectively enantiomers of the antiviral nucleoside analog Valacyclovir hydrochloride (VAL). The chiral separation was performed using normal‐phase high‐performance liquid chromatography (HPLC) with a chiral stationary phase consisting of amylose tris(3‐chloro‐5‐methylphenylcarbamate) and a mobile phase of “ n ‐hexane, methanol, ethanol, and diethylamine”, flow rate of 0.60 mL/min, column temperature of 30°C, injection volume of 10‐μL, detection wavelength of 254‐nm, and run time of 25‐min. The enantiomers (S‐enantiomer, L‐isomer, R‐enantiomer, and D‐isomer) of Valacyclovir were separated with a resolution of 4.8 and no interference. The validation parameters verified for the proposed method, linearity in a range of 0.1002–24.3486 μg/mL (0.02–4.86%) with a regression coefficient of 0.999, and the accuracy was determined with excellent recoveries ranging from 94.38%–109.97%. The concentrations established for the detection limit and quantitation limit were 0.01% and 0.02%, respectively. The forced degradation experiments were used to assess the stability‐indicating qualities. D‐Valacyclovir impurity was successfully evaluated in release and stability samples of VAL in drug substance and tablet dosage forms using the proposed normal phase chiral HPLC approach.
Separation and quantitative estimation of stereo‐selective enantiomers of montelukast in pharmaceutical drug substance and tablets dosage forms by using stability‐indicating normal phase‐HPLC method
Montelukast sodium (MLS) is a leukotriene receptor antagonist that relieves asthma, bronchospasm, allergic rhinitis, and urticaria. A simple, robust, and stability‐indicating normal phase high‐performance liquid chromatography method was developed to separate and quantitatively estimate the S‐enantiomer of MLS. The chiral separation was achieved using USP L51 packing material along with a mobile phase consisting of a solvent mixture (n‐hexane, ethanol, and propionic acid), a flow rate of 1.0 mL/min, a detection wavelength of 284 nm, a column temperature of 30°C and an injection volume of 20 μL. The enantiomers peaks were well separated from the peaks of the placebo, diluting solvent, MLS, and its known impurities with a resolution of more than 2.2 and with no interference. Accuracy and linearity were studied in a range of 0.36–3.597 μg/mL (0.03%–0.30%), with good recoveries between 92.5% and 96.8% and a linear regression coefficient above 0.996. The suggested chiral chromatography method is being considered as an alternative and equivalent method to the United States Pharmacopeia and European Pharmacopeia monographs. The developed method was effectively employed for the study of release and stability samples of MLS. This HPLC method is also capable of separating and estimating the stereo‐selective isomers (R‐ and S‐enantiomers) of sulfoxide impurity of MLS in pharmaceutical medicine.
Separation and quantitative estimation of stereo‐selective enantiomers of montelukast in pharmaceutical drug substance and tablets dosage forms by using stability‐indicating normal phase‐HPLC method
Montelukast sodium (MLS) is a leukotriene receptor antagonist that relieves asthma, bronchospasm, allergic rhinitis, and urticaria. A simple, robust, and stability‐indicating normal phase high‐performance liquid chromatography method was developed to separate and quantitatively estimate the S‐enantiomer of MLS. The chiral separation was achieved using USP L51 packing material along with a mobile phase consisting of a solvent mixture (n‐hexane, ethanol, and propionic acid), a flow rate of 1.0 mL/min, a detection wavelength of 284 nm, a column temperature of 30°C and an injection volume of 20 μL. The enantiomers peaks were well separated from the peaks of the placebo, diluting solvent, MLS, and its known impurities with a resolution of more than 2.2 and with no interference. Accuracy and linearity were studied in a range of 0.36–3.597 μg/mL (0.03%–0.30%), with good recoveries between 92.5% and 96.8% and a linear regression coefficient above 0.996. The suggested chiral chromatography method is being considered as an alternative and equivalent method to the United States Pharmacopeia and European Pharmacopeia monographs. The developed method was effectively employed for the study of release and stability samples of MLS. This HPLC method is also capable of separating and estimating the stereo‐selective isomers (R‐ and S‐enantiomers) of sulfoxide impurity of MLS in pharmaceutical medicine.
- 16 June 2023
- Published by Wiley in Biomedical Chromatography
- Vol. 37 (9) , e5688
Stability‐indicating normal‐phase HPLC method development for separation and quantitative estimation of S‐enantiomer of lacosamide in pharmaceutical drug substance and tablet dosage form
Lacosamide (LA) is an antiepileptic medicine that is used to treat tonic–clonic seizures, partial‐onset seizures, mental problems, and pain. A simple, effective, and reliable normal‐phase liquid chromatographic technique was developed and validated to separate and estimate the enantiomer of (S‐enantiomer) LA in pharmaceutical drug substance and drug product. Normal‐phase LC was performed using USP L40 packing material (250 × 4.6 mm, 5 μm) and a mobile phase of n‐hexane and ethanol at 1.0 ml min−1. The detection wavelength, column temperature, and injection volume used were 210 nm, 25°C, and 20 μl, respectively. The enantiomers (LA and S‐enantiomer) were completely separated using a minimum resolution of 5.8 and accurately quantified without any interference in a 25‐min run time. Accuracy study for stereoselective and enantiomeric purity trials was conducted between 10 and 200%, with recovery values ranging from 99.4 to 103.1% and linear regression values >0.997. The stability‐indicating characteristics were assessed using forced degradation tests. The proposed normal‐phase HPLC technique is an alternate approach to the official monograph methods (USP and Ph.Eur.) of LA, and it was successfully used in the evaluation of release and stability samples for both tablet dosage forms and pharmaceutical substances.
- 16 June 2023
- Published by Wiley in Biomedical Chromatography
- Vol. 37 (9) , e5688
Stability‐indicating normal‐phase HPLC method development for separation and quantitative estimation of S‐enantiomer of lacosamide in pharmaceutical drug substance and tablet dosage form
Lacosamide (LA) is an antiepileptic medicine that is used to treat tonic–clonic seizures, partial‐onset seizures, mental problems, and pain. A simple, effective, and reliable normal‐phase liquid chromatographic technique was developed and validated to separate and estimate the enantiomer of (S‐enantiomer) LA in pharmaceutical drug substance and drug product. Normal‐phase LC was performed using USP L40 packing material (250 × 4.6 mm, 5 μm) and a mobile phase of n‐hexane and ethanol at 1.0 ml min−1. The detection wavelength, column temperature, and injection volume used were 210 nm, 25°C, and 20 μl, respectively. The enantiomers (LA and S‐enantiomer) were completely separated using a minimum resolution of 5.8 and accurately quantified without any interference in a 25‐min run time. Accuracy study for stereoselective and enantiomeric purity trials was conducted between 10 and 200%, with recovery values ranging from 99.4 to 103.1% and linear regression values >0.997. The stability‐indicating characteristics were assessed using forced degradation tests. The proposed normal‐phase HPLC technique is an alternate approach to the official monograph methods (USP and Ph.Eur.) of LA, and it was successfully used in the evaluation of release and stability samples for both tablet dosage forms and pharmaceutical substances.
- 2 December 2022
- Published by Wiley in Biomedical Chromatography
- Vol. 37 (2) , e5549
Degradation pathways and impurity profiling of the anticancer drug apalutamide by HPLC and LC–MS/MS and separation of impurities using Design of Experiments
Apalutamide, an androgen receptor inhibitor, is used to treat prostate cancer. A stability‐indicating high‐performance liquid chromatography method was developed for the estimation of assay and organic impurities of apalutamide in drug substance and in tablet dosages using Design of Experiments. The chromatographic separation was achieved within 30 min using Atlantis dC18, 100 × 4.6 mm, 3.0 μm and the binary gradient program (10 mm KH2PO4, pH 3.5; acetonitrile). The detection wavelength, flow rate, column temperature and injection volume used were 270 nm, 1.0 ml/min, 45°C and 10 μl, respectively. The interaction of independent variables (pH, column temperature and flow rate) and their influences on HPLC parameters were studied using a central composite design, and then the peak separation and elution behaviors between apalutamide and its seven impurities were determined. The method validation was performed for linearity, detection limit, quantitation limit, accuracy, precision and robustness as per the International Conference on Harmonization. A high‐quality recovery with good precision (91.7–106.0%) and correlations (r2 > 0.997) within a linear range of 0.12–2.24 μg/ml (0.05–0.3%, w/w) were achieved consistently for assay and organic impurities of apalutamide. The stability‐indicating characteristics of the proposed method were assessed through forced degradation and mass balance studies. An effort was made to figure out the chemical structures of newly formed degradation products (DP1–DP5) using LC–MS/MS.
- 2 December 2022
- Published by Wiley in Biomedical Chromatography
- Vol. 37 (2) , e5549
Degradation pathways and impurity profiling of the anticancer drug apalutamide by HPLC and LC–MS/MS and separation of impurities using Design of Experiments
Apalutamide, an androgen receptor inhibitor, is used to treat prostate cancer. A stability‐indicating high‐performance liquid chromatography method was developed for the estimation of assay and organic impurities of apalutamide in drug substance and in tablet dosages using Design of Experiments. The chromatographic separation was achieved within 30 min using Atlantis dC18, 100 × 4.6 mm, 3.0 μm and the binary gradient program (10 mm KH2PO4, pH 3.5; acetonitrile). The detection wavelength, flow rate, column temperature and injection volume used were 270 nm, 1.0 ml/min, 45°C and 10 μl, respectively. The interaction of independent variables (pH, column temperature and flow rate) and their influences on HPLC parameters were studied using a central composite design, and then the peak separation and elution behaviors between apalutamide and its seven impurities were determined. The method validation was performed for linearity, detection limit, quantitation limit, accuracy, precision and robustness as per the International Conference on Harmonization. A high‐quality recovery with good precision (91.7–106.0%) and correlations (r2 > 0.997) within a linear range of 0.12–2.24 μg/ml (0.05–0.3%, w/w) were achieved consistently for assay and organic impurities of apalutamide. The stability‐indicating characteristics of the proposed method were assessed through forced degradation and mass balance studies. An effort was made to figure out the chemical structures of newly formed degradation products (DP1–DP5) using LC–MS/MS.